Offshore Protein issued a notice on serious abnormal stock trading fluctuations and risk alerts. The company's revenue from RNA vaccine drug-related products in 2025 accounted for 11.38% of total product revenue, which is relatively low. The company's high-throughput wet testing and data package services that enable AI are still in the early stages of market expansion. As of the first half of 2026, related business revenue accounted for less than 2% of the company's overall revenue. Given that the application of AI in the drug development industry is still in its infancy, there are risks such as rapid technology iteration, long industry verification cycles, and difficulties in commercialization, there is significant uncertainty about the company's future related revenue and profit delivery

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.